Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Hope, Rugo"'
Autor:
Paolo Tarantino, Chiara Corti, Peter Schmid, Javier Cortes, Elizabeth A. Mittendorf, Hope Rugo, Sara M. Tolaney, Giampaolo Bianchini, Fabrice Andrè, Giuseppe Curigliano
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pemb
Externí odkaz:
https://doaj.org/article/617b4ff2dc494ddbbce74ae4065c90c6
Autor:
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide
Externí odkaz:
https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Autor:
Hope Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal Jhaveri, Monica Motwani, Oh Kyu Yoon, Hao Wang, Wendy Verret, Sara Tolaney
Publikováno v:
Cancer Research. 83:GS1-11
Background: HR+/HER2– mBC, the most common subset of breast cancer, is treated with sequential endocrine therapy + targeted agents followed by sequential single-agent chemotherapy (CT), with increasingly shorter benefit duration with each subsequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0456df6c4f83cb82228474fa80e88ba5
https://doi.org/10.1158/1538-7445.sabcs22-gs1-11
https://doi.org/10.1158/1538-7445.sabcs22-gs1-11
Autor:
Frederik Marmé, Aditya Bardia, Hope Rugo, Peter Schmid, Sara M. Tolaney, Mafalda Oliveira, Andreas Schneeweiss, Ling Shi, Wendy Verret, Mahdi Gharaibeh, Anju Shah, Javier Cortés
Publikováno v:
Cancer Research. 83:P4-07
Background: For HR+/HER2- metastatic breast cancer (MBC) patients, after resistance to endocrine therapy (ET), treatment options are mostly limited to traditional chemotherapies (CT) that offer poor survival and quality of life (QoL), creating an are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7563dfd85ab8b4c08925c914d359ac52
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-65
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-65
Autor:
Nadia Harbeck, Shanu Modi, William Jacot, Toshinari Yamashita, Joo Hyuk Sohn, Maria Vidal, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Naoki Niikura, Binghe Xu, Hope Rugo, Konstantinos Papazisis, Javier Cortés, Ian Krop, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, David Cameron
Publikováno v:
Cancer Research. 83:P1-11
Background: DESTINY-Breast04 demonstrated that the HER2 targeting antibody–drug conjugate trastuzumab deruxtecan (T-DXd) significantly prolonged progression-free survival (PFS) and overall survival (OS) vs treatment of physician’s choice (TPC) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0be3aff476fec3f3c5ef21ead8a7341d
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-01
https://doi.org/10.1158/1538-7445.sabcs22-p1-11-01
Autor:
Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara Tolaney, Matthew P. Goetz, Hope Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valerie Andre, Nadia Harbeck, Miguel Martín
Publikováno v:
Cancer Research. 83:GS1-09
Background Adjuvant abemaciclib (a CDK4 and 6 inhibitor) combined with ET resulted in significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients (pts) with HR+, HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5198a4f524def42f0c4897053805a305
https://doi.org/10.1158/1538-7445.sabcs22-gs1-09
https://doi.org/10.1158/1538-7445.sabcs22-gs1-09
Autor:
Hope Rugo, Stephen K. Chia, Javier Cortés, Giuseppe Curigliano, Patrick Neven, Rebecca Dent, Sara Tolaney, Eva Ciruelos, Yeon H. Park, Estelle Roux, Yogesh Chattar, Heather Patino, Murat Akdere, Dejan Juric
Publikováno v:
Cancer Research. 83:PD13-06
Introduction: PIK3CA mutations, seen in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC), are associated with treatment (Tx) resistance and shorter s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2fb63b6ca37cb96be04ab06ec00d2c1
https://doi.org/10.1158/1538-7445.sabcs22-pd13-06
https://doi.org/10.1158/1538-7445.sabcs22-pd13-06
Autor:
Sara Tolaney, Peter Schmid, Aditya Bardia, Frederik Marmé, Delphine Loirat, Priyanka Sharma, Hao Wang, Olivia Fu, Wendy Verret, Hope Rugo
Publikováno v:
Cancer Research. 83:P3-07
Background: SG is a Trop-2-directed antibody-drug conjugate approved by the FDA for patients (pts) with metastatic triple-negative breast cancer who received ≥2 prior chemotherapies (≥1 for MBC). In the phase 3 TROPiCS-02 study, SG demonstrated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b1c8e2ca2171e692aa72fe639132eec
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-08
https://doi.org/10.1158/1538-7445.sabcs22-p3-07-08
Autor:
Neelima Vidula, Senthil Damodaran, Erica L. Blouch, Nora Horick, Nathan Royce Ruffle-Deignan, Manali Bhave, Ami N. Shah, Leticia Varella, Vandana Abramson, Joseph Sparano, Leif Ellisen, Ishraq Alim, Harry Ostrer, Hope Rugo, Aditya Bardia
Publikováno v:
Cancer Research. 83:OT1-11
Background: PARP inhibitors are currently approved for the treatment of germline BRCA1/2 mutant metastatic breast cancer (MBC), which accounts for 5-10% of breast cancer. We hypothesize that a PARP inhibitor may also have efficacy in somatic BRCA1/2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3234158f19bb1061d1102374148b3a3
https://doi.org/10.1158/1538-7445.sabcs22-ot1-11-01
https://doi.org/10.1158/1538-7445.sabcs22-ot1-11-01
Autor:
Dejan Juric, Nicholas Turner, Sherene Loi, Fabrice Andre, Stephen K. Chia, Komal Jhaveri, Patrick Neven, Rebecca Dent, Eva Ciruelos, Mukta Joshi, Estelle Roux, Heather Patino, Murat Akdere, Hope Rugo
Publikováno v:
Cancer Research. 83:P4-09
Introduction: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is mutated in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a440c9c2e678ba158cd565892bfb8269
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-12
https://doi.org/10.1158/1538-7445.sabcs22-p4-09-12